JAK inhibitors for myeloproliferative neoplasms: Clarifying facts from myths

Blood

Volumn 119, Issue 12, 2012, Pages 2721-2730

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 1480; BMS 911543; CYT 387; CYT 3878; JANUS KINASE INHIBITOR; LESTAURTINIB; LY 2784544; NS 018; PACRITINIB; PLACEBO; RUXOLITINIB; SAR 302503; SB 1518; STAT PROTEIN; UNCLASSIFIED DRUG; XL 019;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BLOOD DISEASE; CENTRAL NEUROPATHY; CYTOGENETICS; DIARRHEA; DRUG APPROVAL; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERLIPASEMIA; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NAUSEA; NONHUMAN; PERIPHERAL NEUROPATHY; POLYCYTHEMIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 84858855487     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-395228     Document Type: Review

References (96)

1. Silverstein MN. Myeloproliferative diseases. Postgrad Med J. 1977;61(2):206-210. (Pubitemid 8047201)
2. Wasserman LR. Polycythemia Vera Study Group: a historical perspective. Semin Hematol. 1986; 23(3):183-187.
3. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132-1136.
4. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353(1):33-45. (Pubitemid 41007805)
5. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-124. (Pubitemid 38056222)
6. Barbui T, Barosi G, Birgegard G, et al. Philadelphianegative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011; 29(6):761-770.
7. Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410-2415.
8. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670. (Pubitemid 40446255)
9. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1263 patients with polycythemia vera: an international study. Blood (ASH Annual Meeting Abstracts). 2011;118(21):277.
10. Tefferi A. Annual clinical updates in hematological malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(3):292-301.
11. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-582.
12. European Organization for Research on Treatment of Cancer. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Leukemia and Hematosarcoma Cooperative Group. Br J Cancer. 1981;44(1):75-80.
13. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferonalpha. Cancer. 2006;107(3):451-458. (Pubitemid 44107203)
14. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res. 2005;29(5):481-491. (Pubitemid 40327236)
15. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304(8):441-447. (Pubitemid 11178999)
16. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI,Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986; 23(2):132-143.
17. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29): 3907-3913.
18. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol. 2010;89(12):1233-1237.
19. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internetbased survey of 1179 MPD patients. Cancer. 2007;109(1):68-76. (Pubitemid 46120195)
20. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
21. Tefferi A. How I treat myelofibrosis. Blood. 2011; 117(13):3494-3504.
22. Scott BL, Gooley TA, Sorror ML, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation [published online ahead of print January 10, 2012]. Blood. doi: blood-2011-08-372904.
23. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-3184.
24. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1263 patients with polycythemia vera: an international study. Blood (ASH Annual Meeting Abstracts). 2011;Abstract 277.
25. Tefferi A, Pardanani A, Gangat N, et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. [published online ahead of print January 13, 2012] Leukemia. doi: 10.1038/leu.2011.374.
26. Adamson JW, Fialkow PJ. The pathogenesis of myeloproliferative syndromes. Br J Haematol. 1978;38(3):299-303. (Pubitemid 8316566)
27. Groopman JE. The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med. 1980;92(6):857-858. (Pubitemid 10124380)
28. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011; 118(7):1723-1735.
29. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-1138.
30. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F [published online ahead of print September 13, 2011]. Leukemia. doi:10.1038/leu.2011.253.
31. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011;118(19):5227-5234.
32. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617Fnegative polycythemia vera. Leukemia. 2007; 21(9):1960-1963. (Pubitemid 47299970)
33. Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients [published online ahead of print November 8, 2011]. Leukemia. doi:10.1038/leu.2011.320.
34. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116(6):988-992.
35. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7):e270.
36. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-1148. (Pubitemid 40663494)
37. Bersenev A, Wu C, Balcerek J, et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest. 2010;120(6):2058-2069.
38. Hoermann G, Cerny-Reiterer S, Herrmann H, et al. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. FASEB J. 2012;26(2):894- 906.
39. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-1363.
40. Pardanani A, Lasho T, Finke C, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. [published online ahead of print February 13, 2012] J Clin Oncol. doi:10.1200/JCO.2011.39.0310.
41. Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011;25(11): 1751-1759.
42. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/ JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009;23(8):1441-1445.
43. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010;115(25):5232-5240.
44. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117.
45. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13(4):311- 320.
46. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A. TG101348, a JAK2- selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia. 2008;22(9):1790-1792.
47. Geron I, Abrahamsson AE, Barroga CF, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008;13(4):321-330. (Pubitemid 351446196)
48. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008;111(12): 5663-5671.
49. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009;16(6):487-497.
50. Paquette R, Sokol L, Shah NP, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood (ASH Annual Meeting Abstracts). 2008;112(11):2810.
51. Ma LD, Zhao BH, Walgren R, et al. Efficacy of LY2784544, a small molecule inhibitor selective for mutant JAK2 kinase, in JAK2 V617F-induced hematologic malignancy models. Blood (ASH Annual Meeting Abstracts). 2010;116:4087.
52. Nakaya Y, Shide K, Niwa T, et al. Efficacy of NS- 018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J. 2011;1:e29.
53. Purandare AV, McDevitt TM, Wan H, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2 [published online ahead of print October 21, 2011]. Leukemia. doi:10.1038/leu.2011.292.
54. Ma L, Zhao B, Walgren R, et al. Efficacy of LY2784544, a small molecule inhibitor selective for mutant JAK2 kinase, in JAK2 V617F-induced hematologic malignancy models. Blood (ASH Annual Meeting Abstracts). 2010;116(21):4087.
55. Deshpande A, Reddy MM, Schade GO, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms [published online ahead of print September 16, 2011]. Leukemia. doi:10.1038/ leu.2011.255.
56. Hornakova T, Springuel L, Devreux J, et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica. 2011;96(6):845-853.
57. Wernig G, Kharas MG, Mullally A, et al. EXEL- 8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L [published online ahead of print October 18, 2011]. Leukemia. doi:10.1038/leu.2011.261.
58. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
59. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7): 789-796.
60. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010;115(6):1131-1136.
61. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274- 4281.
62. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-1660. (Pubitemid 44316134)
63. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
64. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
65. Wang X, Zhang W, Tripodi J, et al. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood. 2010;116(26): 5972-5982.
66. Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009; 114(24):5024-5033.
67. Fiskus W, Verstovsek S, Manshouri T, et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res. 2011;17(23):7347-7358.
68. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617Fpositive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110(1):375-379. (Pubitemid 47026857)
69. Shide K, Kameda T, Markovtsov V, et al. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. Blood. 2011;117(25):6866-6875.
70. Pardanani A, Gotlib J, Gupta V, et al. An expanded multicenter phase I/II study of CYT387, a JAK-1/2 inhibitor for the treatment of myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2011; 118(21):3849.
71. Verstovsek S, Mesa RA, Gotlib JR, et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). J Clin Oncol. 2011;29(suppl): Abstract 6500.
72. Verstovsek S, Mesa RA, Gotlib J, et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: results from COMFORT. Blood (ASH Annual Meeting Abstracts). 2011;Abstract 278.
73. Harrison CN, Kiladjian JJ, Al-Ali HK, et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), postpolycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol 29. 2011;29(suppl):Abstract LBA6501.
74. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
75. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455-1457.
76. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006; 108(5):1497-1503. (Pubitemid 44316114)
77. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011; 86(12):1188-1191.
78. Verstovsek S, Kantarjian H, Estrov Z, et al. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy. Blood (ASH Annual Meeting Abstracts). 2011;Abstract 793.
79. Verstovsek S, Estrov Z, Cortes C, et al. The M.D. Anderson Cancer Center (MDACC) experience with ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis: long-term follow-up outcomes of 107 patients from a phase I/II study. Blood (ASH Annual Meeting Abstracts). 2011;Abstract 3851.
80. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/ JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood (ASH Annual Meeting Abstracts). 2010;116(21): 313.
81. Pardanani A, Gotlib J, Jamieson C, et al. SAR302503: interim safety, efficacy and longterm impact on JAK2 V617F allele burden in a phase I/II study in patients with myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2011; Abstract 3838.
82. Pardanani A, Gotlib J, Gupta V, et al. An expanded multicenter phase I/II study of CYT387, a JAK-1/2 inhibitor for the treatment of myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2011; Abstract 3849.
83. Pardanani AD, Caramazza D, George G, et al. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol. 2011;29(15):Abstract 6514.
84. Hexner E, Goldberg JD, Prchal JT, et al. A multicenter, open label phase I/II study of CEP701 (lestaurtinib) in adults with myelofibrosis: a report on phase I. A study of the Myeloproliferative Disorders Research Consortium (MPD-RC). Blood (ASH Annual Meeting Abstracts). 2009;114(22): 754.
85. Moliterno AR, Hexner E, Roboz GJ, et al. An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. Blood (ASH Annual Meeting Abstracts). 2009;114(22):753.
86. Verstovsek S, Odenike O, Scott B, et al. Phase I dose-escalation trial of SB1518, a novel JAK2/ FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/ polycythemia vera myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2009; 114(22):3905.
87. Komrokji R, Wadleigh M, Seymour J, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2011;Abstract 282.
88. Verstovsek S, Mesa R, Kloeker Rhoades S, et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood (ASH Annual Meeting Abstracts). 2011;Abstract 2814.
89. Shah NP, Olszynski P, Sokol L, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, postpolycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2008;112(11):98.
90. Begna KH, Mesa RA, Pardanani A, et al. A phase 2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011;25(2):301-304.
91. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009; 27(27):4563-4569.
92. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108(4):1158-1164. (Pubitemid 44232010)
93. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med. 1988;318(20):1292-1294.
94. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol. 1997;34(1):51-54. (Pubitemid 27063142)
95. Russell RC, Sufan RI, Zhou B, et al. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med. 2011;17(7):845-853.
96. Tefferi A, Jimma T, Gangat N, et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood. 2011;118(17): 4595-4598.